Gilead lands approval of last-hope cancer drug after $12 billion Kite buyout By: San Francisco Business Times via Business Journals October 18, 2017 at 19:10 PM EDT CAR-T therapy is the next great hope for cancer patients, and Gilead has leapfrogged to become an early player in the space. Read More >>
